NCT Number,Study Title,Study URL,Acronym,Study Status,Brief Summary,Study Results,Conditions,Interventions,Primary Outcome Measures,Secondary Outcome Measures,Other Outcome Measures,Sponsor,Collaborators,Sex,Age,Phases,Enrollment,Funder Type,Study Type,Study Design,Other IDs,Start Date,Primary Completion Date,Completion Date,First Posted,Results First Posted,Last Update Posted,Locations,Study Documents
NCT03329690,DS-8201a in Human Epidermal Growth Factor Receptor 2 (HER2)-Expressing Gastric Cancer [DESTINY-Gastric01],https://clinicaltrials.gov/study/NCT03329690,,COMPLETED,"The primary purpose of this trial is to compare the efficacy and safety of DS-8201a and physician's choice treatment in HER2-overexpressing advanced gastric or gastroesophageal junction adenocarcinoma patients who have progressed on two prior treatment regimens including fluoropyrimidine agent, platinum agent, and trastuzumab.",YES,"Neoplasm, Gastrointestinal",DRUG: DS-8201a|DRUG: Physician's Choice,"Percentage of Participants With Objective Response Rate Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set), The Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by independent central imaging review (ICR) based on RECIST version 1.1. CR was defined as a disappearance of all target lesions and PR was defined as at least a 30% decrease in the sum of diameters of target lesions. Unconfirmed ORR (not confirmed by ICR) and confirmed ORR (confirmed by ICR) are reported., Baseline to date of first documented objective response (CR or PR), up to 36 months postdose|Percentage of Participants With Best Overall Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set), The best overall response is the best overall response (BOR) recorded from the start of the study treatment until the end of treatment and includes complete response (CR), partial response (PR), stable disease (SD), progressive disease (PD) and not evaluable (NE) as assessed by independent central imaging review (ICR) based on RECIST version 1.1. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Unconfirmed BOR (not confirmed by ICR) and confirmed BOR (confirmed by ICR) are reported., Baseline to date of first documented objective response, up to 36 months postdose","Overall Survival Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set), Duration of survival follow-up (months) was defined as the date of last contact - date of randomization/ registration + 1.Overall Survival (OS) was defined as the time from the date of randomization (the date of the registration for the Exploratory Cohorts) to the date of death due to any cause., From the date of randomization to the date of death (due to any cause), up to 36 months postdose|Progression-Free Survival Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set), Progression-free survival (PFS) was defined as the time from the date of randomization (the date of the registration for the Exploratory Cohorts) to the earliest date of the first objective documentation of progressive disease (PD) or death due to any cause. PD was defined as at least a 20% increase in the sum of diameters of target lesions., From the date of randomization to the first documented disease progression or date of death (whichever occurs first), up to 36 months postdose|Duration of Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Full Analysis Set), Duration of Response (DOR) was defined as the time from the date of the first documentation of objective response (complete response \[CR\] or partial response \[PR\]) to the date of the first objective documentation of progressive disease (PD) or death due to any cause. DoR was measured for responding subjects (PR or CR) only., From the date of first objective response (CR or PR) to the date of first documentation of PD or death (whichever occurs first), up to 36 months postdose|Disease Control Rate With and Without Confirmation by Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set), Disease control rate (DCR) was defined as the sum of complete response (CR) rate, partial response (PR) rate, and stable disease (SD) rate. As per RECIST v1.1, CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions., Baseline to date of first documented objective response (CR, PR, and SD), up to 36 months postdose|Objective Response Rate and Best Overall Response Based on Independent Central Review Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Intent-to-Treat Analysis Set), The Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by Independent Central Review (ICR) based on RECIST version 1.1. The best overall response is the best overall response (BOR) recorded from the start of the study treatment until the end of treatment and includes CR, PR, stable disease (SD), progressive disease (PD) and not evaluable (NE) as assessed by Investigator based on RECIST version 1.1. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (at least a 20% increase in the sum of diameters of target lesions). Confirmed ORR and BOR (confirmed by ICR) are reported., From randomization to first documented objective response, up to 36 months postdose|Time to Treatment Failure Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Full Analysis Set), Time to treatment failure (TTF) was defined as the time from the date of randomization (the date of the registration for Exploratory Cohorts) to the earliest date of the first objective documentation of progressive disease (PD), death due to any cause, or treatment discontinuation., From date of randomization to first documentation of PD, death due to any cause, or treatment discontinuation (whichever comes first), up to 36 months postdose|Objective Response Rate and Best Overall Response Based on Investigator Assessment Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Response Evaluable Set), The Objective Response Rate (ORR) is the percentage of participants who achieved a best overall response of Complete Response (CR) or Partial Response (PR), assessed by Investigator based on RECIST version 1.1. The best overall response is the best overall response (BOR) recorded from the start of the study treatment until the end of treatment and includes CR, PR, stable disease (SD), progressive disease (PD) and not evaluable (NE) as assessed by Investigator based on RECIST version 1.1. CR was defined as a disappearance of all target lesions, PR was defined as at least a 30% decrease in the sum of diameters of target lesions, and SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD (at least a 20% increase in the sum of diameters of target lesions). Unconfirmed ORR and BOR (not confirmed by Investigator) and confirmed ORR and BOR (confirmed by Investigator) are reported., From randomization to first documented objective response, up to 36 months postdose|Pharmacokinetic Parameter of Maximum Observed Serum Concentration (Cmax) and Trough Serum Concentration (Ctrough) of DS-8201a and Total Anti-HER2 Antibody Following Treatment With DS-8201a, Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. The maximum serum concentration (Cmax) and the trough serum concentration (Ctrough) of DS-8201a were assessed. These serum PK parameters for DS-8201a and total anti-HER2 antibody were estimated in each participant using standard noncompartmental methods., Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)|Pharmacokinetic Parameter of Maximum Observed Serum Concentration (Cmax) and Trough Serum Concentration (Ctrough) of MAAA-1181 Following Treatment With DS-8201a, Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. The maximum serum concentration (Cmax) and the trough serum concentration (Ctrough) of DS-8201a were assessed. These serum PK parameters for MAAA-1181a were estimated in each participant using standard noncompartmental methods., Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)|Pharmacokinetic Parameters of Area Under the Concentration Versus-Time Curve of DS-8201a and Total Anti-HER2 Antibody Following Treatment With DS-8201a, Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. Area under the concentration versus time curve (AUC) from Time 0 to the Last Quantifiable Concentration (AUClast) and Area Under the Concentration versus-Time Curve up to 21 days (AUC21d) are reported. These serum PK parameters for DS-8201a and total anti-HER2 antibody were estimated in each participant using standard noncompartmental methods., Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)|Pharmacokinetic Parameters of Area Under the Concentration Versus-Time Curve of MAAA-1181 Following Treatment With DS-8201a, Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. Area under the concentration versus time curve (AUC) from Time 0 to the Last Quantifiable Concentration (AUClast) and Area Under the Concentration versus-Time Curve up to 21 days (AUC21d) are reported. These serum PK parameters for MAAA-1181a were estimated in each participant using standard noncompartmental methods., Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)|Pharmacokinetic Parameter of Time to Maximum Serum Concentration (Tmax) of DS-8201a, Total Anti-HER2 Antibody and MAAA-1181 Following Treatment With DS-8201a, Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. The time to maximum serum concentration (Tmax) of DS-8201a was assessed. This serum PK parameter for DS-8201a, total anti-HER2 antibody, and MAAA-1181a were estimated in each participant using standard noncompartmental methods., Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)|Pharmacokinetic Parameter Terminal Elimination Half-life (t1/2) of DS-8201a, Total Anti-HER2 Antibody and MAAA-1181 Following Treatment With DS-8201a, Blood samples for DS-8201a pharmacokinetic (PK) analysis were obtained at the specified timepoints. Terminal elimination half-life (t1/2) of DS-8201a was assessed. This serum PK parameter for DS-8201a, total anti-HER2 antibody, and MAAA-1181a were estimated in each participant using standard noncompartmental methods., Cycle 1 and 3, Day 1: predose, 4 hours (h), 7h postdose; Day 8, Day 15, and Day 22 postdose; Cycle 2, Day 1 and Day 22 postdose; Cycle 4, 6, and 8, Day 1 postdose (each cycle is 21 days)|Overall Summary of Treatment-emergent Adverse Events (TEAEs) Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma. (Safety Analysis Set), A treatment-emergent adverse event (TEAE) is defined as an adverse event that occurs, having been absent before the first dose of study drug, or has worsened in severity or seriousness after the initiating the study drug until 47 days after last dose of the study drug. Serious adverse events (SAEs) with an onset or worsening 48 days or more after the last dose of study drug, if considered related to the study treatment, are also TEAEs., Baseline up to 47 days after last dose, up to 36 months postdose|Summary of Most Common Treatment-Emergent Adverse Events (TEAEs) ≥20% of Any Grade by Preferred Term Following Treatment With DS-8201a in Participants With HER2-Expressing Advanced Gastric or Gastroesophageal Junction Adenocarcinoma (Safety Analysis Set), A treatment-emergent adverse event (TEAE) is defined as an adverse event that occurs, having been absent before the first dose of study drug, or has worsened in severity or seriousness after the initiating the study drug until 47 days after last dose of the study drug., Baseline up to 47 days after last dose, up to 36 months postdose",,"Daiichi Sankyo Co., Ltd.",AstraZeneca,ALL,"ADULT, OLDER_ADULT",PHASE2,233,INDUSTRY,INTERVENTIONAL,Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: TREATMENT,DS8201-A-J202|173727|DESTINY-G01,2017-11-02,2019-11-08,2020-12-11,2017-11-06,2020-11-27,2022-03-18,"Aichi Cancer Center Hospital, Nagoya, Aichi, 464-8681, Japan|Hirosaki University Hospital, Hirosaki, Aomori, 036-8563, Japan|National Cancer Center Hospital East, Kashiwa, Chiba, 277-8577, Japan|National Hospital Organization Shikoku Cancer Center, Matsuyama, Ehime, 791-0280, Japan|Japan Community Health Care Organization Kyushu Hospital, Kitakyushu, Fukuoka, 806-8501, Japan|Gunma Prefectural Cancer Center, Ōta, Gunma, 373-8550, Japan|Kure Medical Center, Kure, Hiroshima, 737-0023, Japan|Hokkaido University Hospital, Sapporo, Hokkaido, 060-8648, Japan|Hyogo Cancer Center, Akashi, Hyogo, 673-8558, Japan|Kansai Rosai Hospital, Amagasaki, Hyogo, 660-8511, Japan|Kobe City Medical Center General Hospital, Kobe, Hyogo, 650-0047, Japan|Ibaraki Prefectural Central Hospital, Kasama, Ibaraki, 309-1793, Japan|Kanazawa University Hospital, Kanazawa, Ishikawa, 920-8641, Japan|Iwate Medical University Hospital, Shiwa-gun, Iwate, 028-3695, Japan|Kagawa University Hospital, Kita, Kagawa, 761-0793, Japan|St. Marianna University School of Medicine Hospital, Kawasaki, Kanagawa, 216-8511, Japan|The Kitasato Institute Kitasato University Hospital, Sagamihara, Kanagawa, 252-0375, Japan|Yokohama City University Medical Center, Yokohama, Kanagawa, 232-0024, Japan|Kanagawa Cancer Center, Yokohama, Kanagawa, 241-8515, Japan|Japanese Red Cross Kyoto Daini Hospital, Kamigyō-ku, Kyoto, 602-8026, Japan|Miyagi Cancer Center, Natori, Miyagi, 981-1293, Japan|Osaki Citizen Hospital, Osaki, Miyagi, 989-6183, Japan|Osaka University Hospital, Suita, Osaka, 565-0871, Japan|Toyonaka Municipal Hospital, Toyonaka, Osaka, 560-8565, Japan|Tochigi Cancer Center, Utsunomiya, Tochigi, 320-0834, Japan|Tokyo Metropolitan Komagome Hospital, Bunkyō-Ku, Tokyo, 113-8677, Japan|National Cancer Center Hospital, Chuo Ku, Tokyo, 104-0045, Japan|The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Koto-Ku, Tokyo, 135-8550, Japan|Showa University Koto Toyosu Hospital, Koto-Ku, Tokyo, 135-8577, Japan|Toranomon Hospital, Minato-Ku, Tokyo, 105-8470, Japan|Chiba Cancer Center, Chiba, 260-8717, Japan|Fukui Prefectural Hospital, Fukui, 910-8526, Japan|National Hospital Organization Kyushu Cancer Center, Fukuoka, 811-1395, Japan|Kyushu University Hospital, Fukuoka, 812-8582, Japan|Gifu University Hospital, Gifu, 501-1194, Japan|Hiroshima City Asa Citizens Hospital, Hiroshima, 731-0293, Japan|Hiroshima Prefectural Hospital, Hiroshima, 734-8530, Japan|Kochi Health Sciences Center, Kochi, 781-8555, Japan|Niigata Cancer Center Hospital, Niigata, 951-8566, Japan|Okayama University Hospital, Okayama, 700-8558, Japan|Local Incorporated Administrative Agency Osaka City Hospital Organization Osaka City General Hospital, Osaka, 534-0021, Japan|Osaka International Cancer Institute, Osaka, 541-8567, Japan|Osaka General Medical Center, Osaka, 558-8558, Japan|Kindai University Hospital, Osaka, 589-8511, Japan|Saitama Cancer Center, Saitama, 362-0806, Japan|Shizuoka Cancer Center, Shizuoka, 411-8777, Japan|Shizuoka General Hospital, Shizuoka, 420-8527, Japan|Keio University Hospital, Tokyo, 160-8582, Japan|Chungbuk National University Hospital, Cheongju-si, Chungcheongbuk-do, 28644, Korea, Republic of|National Cancer Center, Ilsan, Gyeonggi-do, 10408, Korea, Republic of|Inje University Haeundae Paik Hospital, Busan, 48108, Korea, Republic of|Dong-A University Hospital, Busan, 49201, Korea, Republic of|Kyungpook National University Chilgok Hospital, Daegu, 41404, Korea, Republic of|Chonnam National University Hwasun Hospital, Gwangju, 58128, Korea, Republic of|Gachon University Gil Medical Center, Incheon, 21565, Korea, Republic of|Chonbuk National University Hospital, Jeonju, 54907, Korea, Republic of|Seoul National University Bundang Hospital, Seongnam, 13620, Korea, Republic of|Korea University Anam Hospital, Seoul, 02841, Korea, Republic of|Seoul National University Hospital, Seoul, 03080, Korea, Republic of|Yonsei Cancer Center, Severance Hospital, Yonsei University Health System, Seoul, 03722, Korea, Republic of|Asan Medical Center, Seoul, 05505, Korea, Republic of|Gangnam Severance Hospital, Seoul, 06273, Korea, Republic of|Samsung Medical Center, Seoul, 06351, Korea, Republic of|The Catholic University of Korea, Seoul St. Mary's Hospital, Seoul, 06591, Korea, Republic of|Chung-Ang University Hospital, Seoul, 06973, Korea, Republic of|Korea University Guro Hospital, Seoul, 08308, Korea, Republic of","Study Protocol and Statistical Analysis Plan, https://cdn.clinicaltrials.gov/large-docs/90/NCT03329690/Prot_SAP_000.pdf"
